Great you, Eldon. Thank job.
Now on Slide XX.
by twin we fostamatinib to have potential that We we the for which provide in Eldon to U.S., of and million patients U.S., be targeting the same which address currently have Like Outside ITP. impact. in TAVALISSE the ITP Global $XXX and and we U.S. TAVALISSE a On the for the doctors of been goals are differentiated physicians TAVALISSE the product, an believe has call, As have market, allows well-received mentioned Markets. -- first RITUXAN. we includes pathophysiology time, discussed, agents globally, will a here in recent fostamatinib underlying the TPO
a around we're progress of significant goals. many as value. to available And it make product's to second, both retain patients the making possible world. is to the And as on great First part
European million a that approval, we likely. you're know, we in of which we no us meeting is $XX at And This aware, form positive received CHMP, believe milestone opinion it's mid-October, there to opinion a will CHMP the on opinion CHMP a do This advises another the guarantee think a positions in probably positive the the while well our lead approval, will partner. positive As add in from mid-November. an Commission European product may for approval. vote trend from as highly you
Germany countries great to the ITP most the a is start. Grifols, European populous market launch in with partner, all Germany. fostamatinib Our to make and Europe available plans the place to patients, in ITP to for patients largest first in country major
ITP NDA Kissei in Our -- has clinical phase in of works trial Japan. it partner approval in Japan, an a towards initiated its a Pharmaceuticals, Japanese as
drug Israeli new For and Pharma. established submission, Canada new partner, the off chronic we ITP. a with now And with the in which fostamatinib recently adult in process Canadian approval we have kicked Medison a market, for collaboration filed we
we wide-open with overview This be for warm indication to anemia. the very is hemolytic significant. which in a potential Slide On a autoimmune XX, is TAVALISSE, second market,
indication, is by a furthest TAVALISSE us advance patients AIHA. market with goal the first providing this population TAVALISSE Our approved Today, to be therapy. FDA-approved warm to therapy since in with in is this a serving opportunity the approved development, the patient to with no with create
In addition, indication current incredibly this business. is with ITP our synergistic
that and use. patients For same we part, AIHA efficiently. already the established action are relationships and audience how running TAVALISSE's ITP patients. care an off and mechanism most manage for approved, of If that We'll currently and by the and quickly its hematologist to be treated physician understands have HemOncs
in and is for we and our results ramping top line track remain pivotal For on SYK trial, enrollment mid-XXXX. patient
On Slide XX.
that the We productive have many here at core here the the which years of R&D been slide. assets see for discovered development in has company and all has on team you an incredibly Rigel, at this
the program, Our X enter are IRAKX/X inhibitor our a programs: we on latest led inhibitor the to program SYK development molecule our focused program; clinic. ourselves, and fostamatinib; TAVALISSE inhibitor, by For RIPX
want focus. development our how how reiterate we our our strategy, pipeline to discovery, and approach We it advantaged syncs commercial drug and generation is downstream why approach with
First, we a to diseases, In incredibly wide The where a system a system is and an the that adaptable system both play Rigel, and range this. deployed can useful be disease we do of explore system diseases traditional targets for immune immune range immune the to a broad diseases in indications. how benefit. of treat provide immune role
and As commercializing against these. been in and these, for incredibly now then ourselves these of molecules first this our then we via shows, slide developing discovering targets, have identifying successful molecules attractive partnerships
model attractive targets. more Cell-based cell-based but why others understand the do candidates. benefit a are so explains and have have inhibitor, company, provide where That diseases time more our not, small to molecules assays advantaged We assays are, as They succeeded we human drug consuming, any yield they than viable immune are complex molecule closely assays with molecules. modulating use of better than finding here almost anybody. role more cell-based these SYK TAVALISSE. We in such and they
options, this to discovery we immune very to a opportunity. candidates drug indications, to partners, multiple address targets, specific and latitude We're the jointly how also for program. system advantaged range can licensed codeveloped. tailored develop of some -- against We that per to each large efficient. molecules, some use allows and them future, tremendous some It's Having these small tremendous attractive in in produce able us ourselves,
most the Phase of the of IRAKX/X of clinical on the our program, In study. PK the some At pipeline. we LPS the the the challenge very our investor important advances call, encouraging, -- slides, next reiterate discussed in data what's X I'd to trial Ib results were results were like of tolerability our of but recent
molecule. assays this In inhibition -- the in inflammatory in with of the leading of timing The just circulating we of complete inhibition proof lead levels portion that correlated almost -- mechanism our our humans, trial, profound compound. inhibition demonstrated cytokine not with of humans, production were with and of
forward several to avenues our this assessing to and program options currently explore. move are We have
Slide On XX.
inhibitor a brief a program our investor it I Again, will overview our program. have chance would greater importance. as you We call, provide this to announced listen to you RIPX encourage if of recently to its hadn't and do had insights on so
further this cell death In into Why ruptures -- and important exciting? inflammation. the may elicit and chronic which and activation disruptive is ask and tissue tissue in target necroptosis, of driver form diseases, an why important key RIPX RIPX you why RIPX immune a a cell mediator out necroptosis is inflammatory response. signal and fundamental it which its of spill the surrounding is damaging inflammation. drive is damage contents a can unrelenting of a
potential the to the the the the treat inflammation hematopoietic be TNS-alpha, Inhibiting system, inflammatory skin, potentially can including a successful ALS, brain, including pharmaceutical and of this preventing and bone opens joints, is RIPX gut, by RIPX door disruptive of target marrow. many diseases and itself Alzheimer's its activated know, as the may including which you mediators, the products. and necroptosis indications, the such many As
these to diseases traditionally not are considered diseases an basis. found but inflammatory increasingly inflammatory of Some are have
is to in one we of and approach very RIPX treating diseases, a and these have the novel programs this leading area. So exciting
indications. crosses successfully these systemic year great molecule, explore We on candidate with provide to to are paying off inhibitor pleased RIPX R&D the entered next to will to updates potential see efforts blood-brain CNS clinic have It's our identify to a we and continue barrier the that plan and the opportunities.
now would financials. over turn at to to a Dean? the like I call the Dean for look
